Enforcement Report - Week of May 17, 2023
Enforcement Report - Week of April 19, 2023
Camber Pharmaceuticals issued a voluntary recall of one lot of atovaquone oral suspension used to treat a form of pneumonia. The recall is due to the potential of microbial contamination of Bacillus cereus.
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product
PISCATAWAY, N.J., March 14, 2023 /PRNewswire/ -- Camber Pharmaceuticals, Inc. is voluntarily recalling lot # E220182 of Atovaquone Oral Suspension, USP 750mg/5mL to the Consumer/User level, due to the potential Bacillus cereus contamination in the product.
As the flu season continues to rage, with the CDC reporting over 23,000 hospitalizations for influenza, several manufacturers have reported shortages of a medicine that can be used to counter it.
Amid a nationwide shortage of Adderall and its generics, add two more companies to the growing list of those that are having difficulty supplying the attention deficit hyperactivity disorder drug.